Stock Analiz

C4 Therapeutics, Inc. CCCC

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026

$2.76Market cap $362M
Open the interactive analysis →

C4 Therapeutics, Inc. (CCCC) is a healthcare company listed in the US with a market value of about $362M. In the twelve months to September 30, 2026 it had revenue of $32M and net income of -$91M, a net margin of -282.2%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -30%.

About C4 Therapeutics

C4 Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. Revenue went from $46M in 2021 to $36M in 2025, a decline of about 5.9% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 70% over three years (dilution for shareholders). It spends 290% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S11.2
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-22.0%
Shareholder yield0.1%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-364.4%
ROIC (5-yr avg.)-30.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$32M$36M$36M$21M$31M$46M——
Net income-$91M-$105M-$105M-$132M-$128M-$84M-$66M-$34M
Free cash flow-$80M-$99M-$65M-$109M-$111M-$88M-$68M$54M
EPS (diluted)$-0.63$-1.27$-1.52$-2.67$-2.62$-1.82$-5.83$-31.03
Net margin-282.2%-292.1%-296.0%-638.3%-412.2%-183.2%——
ROIC—-28.7%-33.5%-34.6%-34.4%-19.0%-19.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $12.50, 353% above the current price; targets range from $6.00 to $30.00; the consensus rating is “Strong buy”; expected EPS is $-0.74 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does C4 Therapeutics pay a dividend?

Not currently.

Is C4 Therapeutics a good stock to buy?

We do not give buy or sell advice. C4 Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.